



Real-World Data on the Use of SGLT2 Inhibitors in Heart Failure: Efficacy and Safety across Diverse Populations


Tomi Siebert*

Unit for Environmental Sciences and Management (UESM), North-West University, South Africa







Abstract

This article explores the real-world evidence on the utilization of sodium-glucose co-transporter 2 (SGLT2) inhibitors in the management of heart failure (HF), focusing on their efficacy and safety profiles across diverse patient populations. While randomized controlled trials have established the cardiovascular benefits of SGLT2 inhibitors, real-world data offer insights into their effectiveness and safety in routine clinical practice. Analysis of electronic health records, administrative claims databases, and other sources reveals consistent reductions in heart failure hospitalizations and cardiovascular mortality with SGLT2 inhibitor use. Importantly, these benefits extend across various subgroups, including elderly patients, individuals with comorbidities such as diabetes mellitus and chronic kidney disease, and diverse racial and ethnic backgrounds. Safety assessments underscore a favorable risk-benefit profile, with low incidences of serious adverse events. Overall, real-world evidence supports the integration of SGLT2 inhibitors into the treatment armamentarium for heart failure, emphasizing the need for personalized approaches to optimize patient outcomes.









Implications for clinical practice



Materials and Methods




Discussion:





Conclusion:



References

1. Kilgore M, Patel HK, Kielhorn A, Maya JF, Sharma P (2017) Economic burden of hospitalizations of medicare beneficiaries with heart failure. *Risk Manag Healthc Policy* 10: 63–70.
2. Nakagawa Y, Kuwahara K (2020) Sodium-glucose cotransporter-2 inhibitors

are potential therapeutic agents for treatment of non-diabetic heart failure patients. *J Cardiol* 76: 123–131.

3. Packer M, Anker SD, Butler J, Filippatos G, Zannad F (2017) Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: Proposal of a novel mechanism of action. *JAMA Cardiol* 2: 1025–1029.
4. McMurray JJV, Solomon SD, Inzucchi SE (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med* 381: 1995–2008. M